Therapeutic effects of cesium-137 radiation in head and neck malignancy

In radiation therapy, many fundamental physical and biological facts and theories must be applied in order to establish a scientific level of practice. There is a voluminous amount of information pertaining to these matters. Cesium-137 is a radioactive nuclide available as a fission product from nuclear reactions. Cesium-137 emits gamma rays at 0.663 MeV. Its half life of about 30 years is an advantage over that of cobalt-60, but cesium-137 is lower, and the specific activity is much less. Author has clinically observed of 150 cases of cesium-137 therapy on head and neck malignancies from Jan. 1971 to Oct. 1978. The following results were observed: 1) Age distribution showed predilection in fifth and decades and sex ratio revealed higher in male than female about 4 times. 2) Laryngeal cancer (34%) maxillary cancer (20.7%) and tongue cancer (12%) occupied high incidence in classification of disease. 3) The cases of radiation only therapeutic group (5000-7000 rad) revealed 61 cases (41.2%) and pre and post operative radiation group (1000-3000 rad) revealed 36 cases (24.3%). 4) In combined therapy (60 cases) arterial infusion group revealed 29 cases and 10 cases of operative group, 11 cases of well prognostic group respectively. (author)